AR-Signaling in Human Malignancies: Prostate Cancer and Beyond
In the 1940s Charles Huggins reported remarkable palliative benefits following surgical castration in men with advanced prostate cancer, and since then the androgen receptor (AR) has remained the main therapeutic target in this disease. Over the past couple of decades, our understanding of AR-signal...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2017-01-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2072-6694/9/1/7 |
| _version_ | 1797708308755251200 |
|---|---|
| author | Michael T. Schweizer Evan Y. Yu |
| author_facet | Michael T. Schweizer Evan Y. Yu |
| author_sort | Michael T. Schweizer |
| collection | DOAJ |
| description | In the 1940s Charles Huggins reported remarkable palliative benefits following surgical castration in men with advanced prostate cancer, and since then the androgen receptor (AR) has remained the main therapeutic target in this disease. Over the past couple of decades, our understanding of AR-signaling biology has dramatically improved, and it has become apparent that the AR can modulate a number of other well-described oncogenic signaling pathways. Not surprisingly, mounting preclinical and epidemiologic data now supports a role for AR-signaling in promoting the growth and progression of several cancers other than prostate, and early phase clinical trials have documented preliminary signs of efficacy when AR-signaling inhibitors are used in several of these malignancies. In this article, we provide an overview of the evidence supporting the use of AR-directed therapies in prostate as well as other cancers, with an emphasis on the rationale for targeting AR-signaling across tumor types. |
| first_indexed | 2024-03-12T06:19:29Z |
| format | Article |
| id | doaj.art-27f1d160446d49e785e4f74ecf04d3b8 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T06:19:29Z |
| publishDate | 2017-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-27f1d160446d49e785e4f74ecf04d3b82023-09-03T02:17:32ZengMDPI AGCancers2072-66942017-01-0191710.3390/cancers9010007cancers9010007AR-Signaling in Human Malignancies: Prostate Cancer and BeyondMichael T. Schweizer0Evan Y. Yu1Division of Oncology, Department of Medicine, University of Washington, Seattle, WA 98109, USADivision of Oncology, Department of Medicine, University of Washington, Seattle, WA 98109, USAIn the 1940s Charles Huggins reported remarkable palliative benefits following surgical castration in men with advanced prostate cancer, and since then the androgen receptor (AR) has remained the main therapeutic target in this disease. Over the past couple of decades, our understanding of AR-signaling biology has dramatically improved, and it has become apparent that the AR can modulate a number of other well-described oncogenic signaling pathways. Not surprisingly, mounting preclinical and epidemiologic data now supports a role for AR-signaling in promoting the growth and progression of several cancers other than prostate, and early phase clinical trials have documented preliminary signs of efficacy when AR-signaling inhibitors are used in several of these malignancies. In this article, we provide an overview of the evidence supporting the use of AR-directed therapies in prostate as well as other cancers, with an emphasis on the rationale for targeting AR-signaling across tumor types.http://www.mdpi.com/2072-6694/9/1/7prostate cancerbreast cancerbladder cancerrenal cell carcinomapancreatic cancerovarian cancerhepatocellular cancerovarian cancerendometrial cancerandrogen receptor |
| spellingShingle | Michael T. Schweizer Evan Y. Yu AR-Signaling in Human Malignancies: Prostate Cancer and Beyond Cancers prostate cancer breast cancer bladder cancer renal cell carcinoma pancreatic cancer ovarian cancer hepatocellular cancer ovarian cancer endometrial cancer androgen receptor |
| title | AR-Signaling in Human Malignancies: Prostate Cancer and Beyond |
| title_full | AR-Signaling in Human Malignancies: Prostate Cancer and Beyond |
| title_fullStr | AR-Signaling in Human Malignancies: Prostate Cancer and Beyond |
| title_full_unstemmed | AR-Signaling in Human Malignancies: Prostate Cancer and Beyond |
| title_short | AR-Signaling in Human Malignancies: Prostate Cancer and Beyond |
| title_sort | ar signaling in human malignancies prostate cancer and beyond |
| topic | prostate cancer breast cancer bladder cancer renal cell carcinoma pancreatic cancer ovarian cancer hepatocellular cancer ovarian cancer endometrial cancer androgen receptor |
| url | http://www.mdpi.com/2072-6694/9/1/7 |
| work_keys_str_mv | AT michaeltschweizer arsignalinginhumanmalignanciesprostatecancerandbeyond AT evanyyu arsignalinginhumanmalignanciesprostatecancerandbeyond |